Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.
Tanaka H, Hirata M, Shinonome S, Wada T, Iguchi M, Dohi K, Inoue M, Ishioka Y, Hojo K, Yamada T, Sugimoto T, Masuno K, Nezasa K, Sato N, Matsuo K, Yonezawa S, Frenkel EP, Shichijo M.
Tanaka H, et al. Among authors: shichijo m.
Cancer Sci. 2014 Aug;105(8):1040-8. doi: 10.1111/cas.12449.
Cancer Sci. 2014.
PMID: 24837299
Free PMC article.